Singapore markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
51.01+0.98 (+1.96%)
At close: 04:00PM EDT
51.29 +0.28 (+0.55%)
After hours: 06:33PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close50.03
Bid49.80 x 1200
Ask51.32 x 1800
Day's range50.17 - 51.01
52-week range46.93 - 58.10
Avg. volume2,525,869
Market cap127.388B
Beta (5Y monthly)0.36
PE ratio (TTM)18.42
Earnings dateN/A
Forward dividend & yield1.75 (3.42%)
Ex-dividend date26 May 2022
1y target estN/A
  • CNW Group

    Dupixent® (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation

    Today sanofi-aventis Canada Inc. (Sanofi Canada) announced the expanded approval of Dupixent® (dupilumab injection) as an add-on maintenance treatment in patients aged six to 11 years with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma. The approval is based on the pivotal VOYAGE phase 3 trial which enrolled 408 children aged six to 11 years with uncontrolled moderate- to severe asthma. The primary endpoint of the trial was the annualized rate of sev

  • CNW Group

    Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer

    Today sanofi-aventis Canada Inc. (Sanofi) announced the approval of Libtayo® (cemiplimab) for the treatment of adult patients with cervical cancer who have progressed on or after prior platinum-based chemotherapy and who require additional systemic therapy to treat recurrent or metastatic disease. The approval is based on the Phase 3 EMPOWER-Cervical 1 Study of Cemiplimab in Adults With Cervical Cancer (NCT03257267). The trial, which was the largest-ever randomized clinical trial in advanced cer

  • Business Wire

    Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates

    BOTHELL, Wash. & PARIS, March 16, 2022--Seagen Inc. (Nasdaq:SGEN) and Sanofi today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and Sanofi currently has o